3-(difluoromethyl)-1-(4-methoxyphenyl)-5-(4-(methylsulfinyl)phenyl)pyrazole has been researched along with naloxone in 3 studies
| Studies (3-(difluoromethyl)-1-(4-methoxyphenyl)-5-(4-(methylsulfinyl)phenyl)pyrazole) | Trials (3-(difluoromethyl)-1-(4-methoxyphenyl)-5-(4-(methylsulfinyl)phenyl)pyrazole) | Recent Studies (post-2010) (3-(difluoromethyl)-1-(4-methoxyphenyl)-5-(4-(methylsulfinyl)phenyl)pyrazole) | Studies (naloxone) | Trials (naloxone) | Recent Studies (post-2010) (naloxone) |
|---|---|---|---|---|---|
| 11 | 0 | 0 | 20,134 | 1,257 | 3,321 |
| Protein | Taxonomy | 3-(difluoromethyl)-1-(4-methoxyphenyl)-5-(4-(methylsulfinyl)phenyl)pyrazole (IC50) | naloxone (IC50) |
|---|---|---|---|
| Cytochrome P450 2D6 | Homo sapiens (human) | 2 | |
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.043 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0219 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0019 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0019 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.0397 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.1896 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.05 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.0795 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 0.0154 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0089 | |
| Beta-2 adrenergic receptor | Cavia porcellus (domestic guinea pig) | 0.0055 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, T; Jobo-Magari, K; Matsumori, K; Ochi, T; Yonezawa, A | 1 |
| Fujii, T; Goto, T; Motoyama, Y; Ochi, T | 2 |
3 other study(ies) available for 3-(difluoromethyl)-1-(4-methoxyphenyl)-5-(4-(methylsulfinyl)phenyl)pyrazole and naloxone
| Article | Year |
|---|---|
Anti-inflammatory and analgesic effects of a novel pyrazole derivative, FR140423.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Dinoprostone; Dose-Response Relationship, Drug; Female; Fungi; Indomethacin; Isoenzymes; Male; Membrane Proteins; Molecular Structure; Naloxone; Pain Measurement; Peptic Ulcer; Peroxidases; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyrazolones; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Recombinant Proteins; Sulfoxides | 1999 |
Antinociceptive properties of FR140423 mediated through spinal delta-, but not mu- and kappa-, opioid receptors.
Topics: Administration, Oral; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Binding, Competitive; Diarrhea; Injections, Intraventricular; Injections, Spinal; Male; Membranes; Naloxone; Naltrexone; Narcotic Antagonists; Pain; Pain Measurement; Pyrazoles; Rats; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Spinal Cord; Sulfoxides | 1999 |
The profile of FR140423, a novel anti-inflammatory compound, in yeast-induced rat hyperalgesia.
Topics: Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Dose-Response Relationship, Drug; Hyperalgesia; Indomethacin; Injections, Subcutaneous; Male; Morphine; Naloxone; Narcotic Antagonists; Pyrazoles; Rats; Rats, Sprague-Dawley; Saccharomyces cerevisiae; Sulfoxides | 1999 |